News
VALN
5.57
-6.07%
-0.36
D.E. Shaw discloses net short position in Valneva shares
PUBT · 4h ago
Sonoco Products Posts Downbeat Q1 Results, Joins Target Hospitality, Calix And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga · 6h ago
Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Benzinga · 8h ago
Valneva downgraded to Sell from Neutral at Goldman Sachs
TipRanks · 9h ago
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN)
TipRanks · 10h ago
ANALYSIS-COVID shots, newer vaccines in limbo after US court halts Kennedy’s advisory panel
Reuters · 1d ago
Weekly Report: what happened at VALN last week (0413-0417)?
Weekly Report · 2d ago
Valneva price target lowered to $11 from $13 at Guggenheim
TipRanks · 6d ago
Weekly Report: what happened at VALN last week (0406-0410)?
Weekly Report · 04/13 10:39
Weekly Report: what happened at VALN last week (0330-0403)?
Weekly Report · 04/06 10:39
Valneva reports 173.9 million issued shares, 188.5 million total voting rights
Reuters · 04/03 06:30
First Berlin reiterates Valneva Buy, cuts target price to EUR 4.8
Reuters · 03/31 21:19
Weekly Report: what happened at VALN last week (0323-0327)?
Weekly Report · 03/30 10:40
Valneva (0OB3) Receives a Rating Update from a Top Analyst
TipRanks · 03/28 01:39
Catalyst Watch: Jobs report, Nike earnings, and Apple turns 50
Seeking Alpha · 03/27 19:00
Valneva Showcases Chikungunya Vaccine Progress at World Vaccine Congress in Washington
TipRanks · 03/26 17:18
Valneva to attend multiple events at the 26th World Vaccine Congress
Reuters · 03/26 16:46
Valneva (0OB3) Receives a Rating Update from a Top Analyst
TipRanks · 03/25 07:56
VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study
NASDAQ · 03/24 16:12
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 03/24 12:05
More
Webull provides a variety of real-time VALN stock news. You can receive the latest news about Valneva Se through multiple platforms. This information may help you make smarter investment decisions.
About VALN
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.